Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

CCK antagonists from Warner-Lambert

Aug. 30, 1996

NGD-95-1 demonstrates safety in phase I

Aug. 30, 1996

More squalene synthase inhibitors from Pfizer

Aug. 30, 1996

Xenical to be marketed in 1997

Aug. 30, 1996

SDZ-266806: A novel squalene synthase inhibitor

Aug. 30, 1996

Estrogenic compounds from Sankyo

Aug. 30, 1996

Prophylactic tibolone shown effective in 2 year study

Aug. 30, 1996

Columbia Laboratories granted U.S. patent for Crinone technology

Aug. 23, 1996

Astra's Atmos launched in Sweden

Aug. 23, 1996

Humatrope approved for new indication in U.S.

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...